Amneal Pharmaceuticals (AMRX) Operating Leases (2019 - 2026)

Amneal Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $13.5 million for Q1 2026.

• In Q1 2026, Operating Leases rose 58.06% year-over-year to $13.5 million; the TTM figure through Mar 2026 stood at $13.5 million (up 58.06% YoY), while the FY2025 annual figure was $14.2 million, down 69.82% from the prior year.
• Operating Leases was $13.5 million for Q1 2026 at Amneal Pharmaceuticals, down from $14.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $59.2 million in Q4 2022 to a low of $8.5 million in Q1 2025.
• Historically, Operating Leases has averaged $24.0 million across 5 years, with a median of $16.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Operating Leases jumped 76.65% in 2024, then plunged 69.82% in 2025.
• A 5-year view of Operating Leases shows it stood at $59.2 million in 2022, then retreated by 17.42% to $48.9 million in 2023, then dropped by 3.84% to $47.0 million in 2024, then slumped by 69.82% to $14.2 million in 2025, then dropped by 5.13% to $13.5 million in 2026.
• The last three Operating Leases figures came in at $13.5 million (Q1 2026), $14.2 million (Q4 2025), and $15.7 million (Q3 2025), per Business Quant data.